CIHEXA

Indications

• Vaccination against infectious diseases
• Allergy testing and immunotherapy
• Monoclonal antibody production
• Transplantation to prevent organ rejection

Dosage

Children: Dosing of antigens in children also depends on the specific antigen and the clinical indication. For pediatric vaccinations, refer to the BNF for Children.

Adults: Dosing of antigens is highly variable and depends on the specific antigen and the clinical indication. For vaccine administration, refer to national immunization guidelines.

Mechanism of action

Antigens work by binding to specific receptors on the surface of immune cells, such as B cells and T cells. This binding triggers a cascade of immune responses, including the proliferation of specific immune cell populations and the production of antibodies that target the antigen. This process is crucial for the development of adaptive immunity, allowing the body to remember and respond more effectively to future encounters with the same antigen.

Pharmacodynamics

The pharmacodynamics of antigens involve the interaction with the immune system to elicit a response. The magnitude and quality of this response can vary based on several factors, including the nature of the antigen, the route of exposure, and the host's immune status. Antigens can be classified as T-cell dependent or T-cell independent, influencing the type of immune response generated.

Pharmacokinetics

Antigens are processed by antigen-presenting cells (APCs) that present peptide fragments to T cells. The pharmacokinetics of antigens can vary widely depending on their form (e.g., live attenuated, inactivated, or subunit vaccines). Generally, once introduced into the body, antigens are taken up by APCs, which then migrate to lymph nodes to activate T and B cells. The duration of immune response can be influenced by the type of antigen and the presence of adjuvants.

Pregnancy

Safety during pregnancy depends on the specific type of antigen. Consult relevant guidelines for specific antigens.

Breast-feeding

Safety during breastfeeding varies by antigen type. Consult relevant guidelines for specific antigens.

Storage

Store at controlled room temperature, away from light and moisture. Specific storage conditions may vary based on the type of antigen.

Indications

• Whooping cough (pertussis)
• Respiratory tract infections caused by Bordetella species

Dosage

Adults: Refer to the B

Mechanism of action

Bordetella pertussis causes disease by adhering to the ciliated epithelial cells of the respiratory tract, leading to inflammation and disruption of normal respiratory function. The bacteria produce various virulence factors, including pertussis toxin, which interferes with host immune responses and causes systemic effects. The toxin primarily acts on the adenylate cyclase system, increasing cAMP levels, which disrupts cellular signaling pathways and contributes to the characteristic symptoms of whooping cough.

Pharmacodynamics

The symptoms of Bordetella infections, particularly whooping cough, are largely due to the host's immune response to the bacterial infection and the effects of the pertussis toxin. The disease progresses through stages, including the catarrhal stage (with mild symptoms), the paroxysmal stage (with severe coughing), and the convalescent stage (gradual recovery). Treatment may involve antibiotics to reduce the duration of symptoms and prevent transmission, although they do not significantly alter the course of the illness once the paroxysmal stage has begun.

Pharmacokinetics

As Bordetella is a bacterium, traditional pharmacokinetic parameters do not apply in the same way as for pharmaceuticals. The bacteria colonize the respiratory tract and can persist in the mucosal tissues, leading to prolonged symptoms. Antibiotics such as macrolides, which are commonly used to treat Bordetella infections, demonstrate variable absorption, distribution, metabolism, and excretion profiles depending on the specific drug used. For example, azithromycin has a long half-life and good tissue penetration.

Pregnancy

Bordetella pertussis vaccines are generally considered safe during pregnancy and are recommended to protect both the mother and the newborn from whooping cough.

Breast-feeding

The Bordetella pertussis vaccine can be administered during breastfeeding, as it is not known to pose a risk to nursing infants.

Storage

Store Bordetella pertussis vaccine in a refrigerator at temperatures between 2°C and 8°C. Do not freeze.

Formulations

• Bordetella pertussis vaccine (inactivated)
• Combination vaccines (e.g., DTaP - Diphtheria, Tetanus, and Pertussis)

Indications

• Cancer therapy
• Autoimmune diseases
• Infectious diseases
• Targeted drug delivery systems
• Vaccination strategies

Dosage

Children: Refer to specific product guidelines for dosing information, as it varies widely based on the conjugate and indication.

Adults: Refer to specific product guidelines for dosing information, as it varies widely based on the conjugate and indication.

Mechanism of action

The mechanism of action of conjugate drugs varies widely depending on the specific substances involved in the conjugation. Generally, conjugation can facilitate drug uptake into cells, enhance bioavailability, and alter the pharmacokinetics of the active drug. Some conjugates are designed to target specific receptors or tissues, thereby improving the specificity and efficacy of the therapeutic effect.

Pharmacodynamics

Pharmacodynamics of conjugate drugs is largely dependent on the nature of the conjugated entities. They may exhibit altered binding affinities, modified distribution profiles, and varying degrees of activity compared to their non-conjugated counterparts. The therapeutic effect could be amplified or diminished based on the conjugation strategy employed, with implications for potency and duration of action.

Pharmacokinetics

Pharmacokinetics of conjugate drugs is influenced by the characteristics of both the parent drug and the conjugated moiety. Factors such as absorption, distribution, metabolism, and excretion (ADME) can be significantly altered. Conjugates may exhibit improved solubility and permeability, leading to enhanced absorption and bioavailability. Metabolic pathways may also be modified, potentially altering the half-life and clearance rates of the drug.

Pregnancy

The safety of conjugate vaccines during pregnancy has not been fully established. Use during pregnancy should be based on the benefit-to-risk assessment.

Breast-feeding

Conjugate vaccines are generally considered safe during breastfeeding. Vaccination can be beneficial for the infant when the mother is immunized.

Storage

Conjugate vaccines should be stored in a refrigerator at 2-8 degrees Celsius and protected from light. Do not freeze.

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Bronchitis

Dosage

Children: Refer to specific antibiotic guidelines for pediatric dosing based on the type and severity of the infection caused by Haemophilus species.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of the infection caused by Haemophilus species.

Mechanism of action

H. influenzae adheres to epithelial cells via pili and other surface structures, allowing colonization of the nasopharynx. The encapsulated strains evade phagocytosis due to their polysaccharide capsule, which inhibits opsonization and complement activation. This leads to the systemic spread of the bacteria and can result in severe infections if not effectively treated.

Pharmacodynamics

H. influenzae can produce various virulence factors, including polysaccharide capsules, endotoxins, and enzymes that contribute to its pathogenicity. The bacteria can resist the effects of certain antibiotics through mechanisms such as beta-lactamase production, which hydrolyzes beta-lactam antibiotics, rendering them ineffective. The host's immune response is often inadequate to clear the infection due to the bacterium's ability to evade immune detection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat H. influenzae infections vary based on the specific drug. Common antibiotics include ampicillin and ceftriaxone. The absorption, distribution, metabolism, and excretion depend on the antibiotic used. For example, ampicillin is well absorbed from the gastrointestinal tract, widely distributed in body tissues and fluids, and eliminated primarily via renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Rash
• Irritability
• Anaphylaxis (rare)

Precautions

• Caution in patients with a history of severe allergic reactions
• Monitor for signs of anaphylaxis after administration
• Assess for underlying immunocompromised conditions

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral tablets

Indications

• Hepatitis A
• Hepatitis B
• Influenza
• Polio
• Rabies
• Typhoid fever

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it varies by vaccine type and indication.

Adults: Refer to specific product guidelines for adult dosing, as it varies by vaccine type and indication.

Mechanism of action

Inactivated vaccines work by introducing a form of the pathogen that cannot cause disease into the body. This stimulates the immune system to produce antibodies and memory cells specific to the pathogen, allowing for a robust immune response upon future exposure. The immune system recognizes the inactivated pathogen as foreign, leading to the activation of T-cells and B-cells, which are crucial for long-term immunity.

Pharmacodynamics

The pharmacodynamics of inactivated vaccines involve the generation of an adaptive immune response. After vaccination, the body produces specific antibodies against the inactivated pathogen. The response typically includes both humoral immunity, characterized by antibody production, and cellular immunity, involving T-cell activation. The duration of immunity can vary, and booster doses may be required to maintain adequate protection.

Pharmacokinetics

Inactivated vaccines do not have a pharmacokinetic profile like traditional drugs since they do not enter systemic circulation in the same manner. Following administration, the vaccine components are taken up by antigen-presenting cells, which process and present the antigens to T-cells. The immune response is initiated locally at the site of injection and can be influenced by factors such as the route of administration and the presence of adjuvants that enhance the immune response.

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Headache
• Myalgia
• Chills

Precautions

• Assess for allergies to vaccine components
• Monitor for allergic reactions post-administration
• Consider underlying health conditions that may affect immune response

Pregnancy

Inactivated vaccines are generally considered safe during pregnancy, but individual risk-benefit assessment is recommended.

Breast-feeding

Inactivated vaccines can be administered during breastfeeding without concern for adverse effects in the infant.

Storage

Store in a refrigerator at 2°C to 8°C. Do not freeze.

Formulations

• Inactivated viral vaccines
• Inactivated bacterial vaccines

Indications

• Influenza virus infection
• Prophylaxis of influenza in high-risk populations
• Treatment of suspected or confirmed influenza in children and adults

Dosage

Children: Refer to the specific antiviral medication's product information for dosing guidance.

Adults: Refer to the specific antiviral medication's product information for dosing guidance.

Mechanism of action

Antiviral medications targeting influenza, such as neuraminidase inhibitors (e.g., oseltamivir), work by inhibiting the neuraminidase enzyme on the surface of the virus. This inhibition prevents the release of new viral particles from infected cells, thus limiting the spread of the virus within the respiratory tract.

Pharmacodynamics

The pharmacodynamic effects of antiviral agents against influenza include a reduction in the severity and duration of symptoms, as well as a decrease in the viral load. Neuraminidase inhibitors are most effective when administered within 48 hours of the onset of symptoms, as they can significantly reduce the duration of illness and the risk of complications.

Pharmacokinetics

Antivirals such as oseltamivir are administered orally and are quickly absorbed from the gastrointestinal tract. The drug is converted to its active form, oseltamivir carboxylate, primarily in the liver. It has a half-life of approximately 6 to 10 hours and is predominantly eliminated via the kidneys. Patients with renal impairment may require dose adjustments to avoid toxicity.

Pregnancy

Consult healthcare provider for risks and benefits.

Breast-feeding

Consult healthcare provider for risks and benefits.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Prevention of poliomyelitis
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for appropriate dosing schedules and recommendations for poliovirus vaccination in children.

Adults: Refer to specific guidelines for IPV and OPV administration in adults, as vaccination schedules may vary based on age and immunization history.

Mechanism of action

Poliovirus primarily infects the motor neurons of the spinal cord and brainstem, leading to cell lysis and apoptosis. The viral replication occurs in the cytoplasm of the host cells, resulting in the release of new virions. The immune response triggered by the infection can lead to paralysis due to damage to the motor neurons.

Pharmacodynamics

The pharmacodynamics of polio vaccines involve the induction of an immune response against the poliovirus. The IPV induces serum neutralizing antibodies, while the OPV induces both serum and mucosal immunity. This immune response prevents the establishment of infection and protects against the disease.

Pharmacokinetics

Poliovirus vaccines do not have a pharmacokinetic profile in the traditional sense, as they are biological products. However, the IPV is administered intramuscularly, leading to systemic absorption and subsequent immunogenicity. The OPV is administered orally, leading to replication in the gastrointestinal tract and inducing both humoral and cellular immunity.

Contra-indications

• Severe allergic reaction to polio vaccine components
• Immunocompromised state (inactivated vaccine preferred)

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Gastrointestinal disturbances (nausea, vomiting)
• Rarely, vaccine-derived paralytic poliomyelitis

Interactions

• Live vaccines may be affected by immunosuppressive therapies
• Concurrent administration with other vaccines is generally safe but consult vaccination guidelines

Precautions

• History of allergic reactions
• Patients with a history of Guillain-Barré syndrome
• Caution in patients with neurological disorders

Pregnancy

Polio vaccination is recommended during pregnancy if the woman is at risk of exposure, as the benefits outweigh potential risks.

Breast-feeding

Polio vaccine can be administered to breastfeeding mothers without risk to the infant.

Storage

Store at 2-8°C. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Topical treatment of skin conditions
• Emulsifying agents in pharmaceutical formulations
• Wound healing applications
• Delivery of poorly soluble drugs

Dosage

Children: Refer to specific product guidelines and BNF for appropriate dosing regimens.

Adults: Refer to specific product guidelines and BNF for appropriate dosing regimens.

Mechanism of action

Surface-active agents, or surfactants, lower the surface tension between two substances, such as between a liquid and a solid or between two liquids. This property enables them to spread easily and improve the solubility of drugs in various formulations. In the context of drug delivery, surfactants can facilitate the absorption of medications across biological membranes by disrupting lipid bilayers, thus enhancing bioavailability.

Pharmacodynamics

Pharmacodynamics refers to the effects of drugs on the body and their mechanisms of action. For surface-active agents, the pharmacodynamic properties include their ability to alter surface tension and enhance wetting, spreading, and emulsification. These properties allow for improved penetration of active ingredients into tissues and can enhance the therapeutic effects of topically applied drugs.

Pharmacokinetics

Pharmacokinetics involves the absorption, distribution, metabolism, and excretion (ADME) of drugs. Surface-active agents typically exhibit limited systemic absorption when applied topically, leading to localized effects. The rate of absorption can be influenced by the formulation, the presence of other excipients, and the condition of the skin or mucosal surface. Metabolism may occur to a minimal extent, and excretion primarily happens through the skin or via the lymphatic system.

Pregnancy

Consult healthcare professional before use.

Breast-feeding

Consult healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine

Indications

• Diphtheria prophylaxis
• Tetanus prophylaxis
• Pertussis prophylaxis (when combined with other vaccines)

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations for pediatric immunization with toxoids.

Adults: Refer to specific guidelines for each toxoid vaccine, as dosing may vary based on the type of vaccine and individual patient factors.

Mechanism of action

Toxoids work by stimulating the immune system to produce antibodies against the toxin without causing disease. When administered, the immune system recognizes the toxoid as a foreign substance and generates a specific immune response. This includes the production of immunoglobulin G (IgG) antibodies that can neutralize the active toxin if the individual is exposed to the bacteria in the future.

Pharmacodynamics

The pharmacodynamics of toxoids involve the activation of the adaptive immune response. After vaccination, dendritic cells present the antigen to T cells, which then help B cells differentiate into plasma cells that produce specific antibodies. The presence of these antibodies provides immunity against the toxin by neutralizing its effects, thereby preventing the disease associated with the original bacterial toxin.

Pharmacokinetics

Toxoids are typically administered via intramuscular or subcutaneous injection. Following administration, they are gradually taken up by antigen-presenting cells, which then process and present the toxoid to T cells. The immunogenic response can develop over several weeks. The duration of immunity can vary, necessitating booster doses to maintain adequate antibody levels over time.

Adverse effects

• Local reactions at the injection site, such as pain, swelling, or redness.
• Fever.
• Fatigue.
• Headache.
• Allergic reactions in rare cases.

Precautions

• Use with caution in individuals with a history of severe allergic reactions to a vaccine component.
• Monitor patients for allergic reactions post-vaccination.

Pregnancy

Toxoids are generally considered safe during pregnancy; however, consultation with a healthcare provider is recommended.

Breast-feeding

Toxoids are considered safe for use during breastfeeding.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Diphtheria toxoid
• Tetanus toxoid
• Pertussis toxoid

Indications

• Prevention of hepatitis A virus infection
• Prevention of hepatitis B virus infection
• Post-exposure prophylaxis for hepatitis A
• Occupational vaccination for healthcare workers
• Vaccination for travelers to endemic areas

Dosage

Children: Refer to BNF for Children for pediatric vaccination schedules, which may include age-specific dosing recommendations.

Adults: Refer to specific guidelines or BNF for adult vaccination schedules, typically involving a series of doses based on the specific vaccine type.

Mechanism of action

The mechanism of action of hepatitis vaccines involves the introduction of inactivated virus particles or recombinant proteins that mimic the hepatitis viruses. This exposure prompts the immune system to produce antibodies against the hepatitis antigens. Upon subsequent exposure to the actual virus, the immune system can rapidly respond by deploying these antibodies, thus preventing the disease.

Pharmacodynamics

The pharmacodynamics of hepatitis vaccines is characterized by the induction of both humoral and cellular immune responses. Following vaccination, there is an increase in specific IgG antibody levels against hepatitis A or B. The immune memory created by the vaccine allows for a quicker and more effective response upon real virus exposure. The vaccines are generally well-tolerated and elicit minimal side effects, primarily localized reactions at the injection site.

Pharmacokinetics

Hepatitis vaccines are administered via intramuscular injection. The pharmacokinetics of the vaccine is not described in terms of absorption, distribution, metabolism, and excretion like traditional drugs, as the active components (antigens) do not circulate in the body like pharmaceuticals. Instead, the immune response is the primary endpoint of interest, which can be measured by antibody titers in the blood post-vaccination. Immunogenicity is typically evaluated through serological assays to confirm protective antibody levels.

Contra-indications

• Severe allergic reaction to any component of the vaccine
• Severe immunosuppression in certain cases

Adverse effects

• Injection site reactions (pain, redness, swelling)
• Fever
• Fatigue
• Headache
• Nausea

Interactions

• May interact with immunosuppressive therapies, potentially reducing vaccine efficacy
• Concurrent administration of other vaccines should be assessed for individual patient circumstances

Precautions

• Evaluate patients for allergies prior to vaccination
• Monitor patients with a history of Guillain-Barré syndrome
• Consider the patient's overall health and immunocompromised status

Pregnancy

Vaccination is generally considered safe during pregnancy, particularly in high-risk populations, but should be discussed with a healthcare provider.

Breast-feeding

Vaccination is considered safe during breastfeeding and does not contraindicate breastfeeding.

Storage

Store in a refrigerator at 2 to 8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Inactivated vaccine for hepatitis A
• Inactivated vaccine for hepatitis B

Indications

• Prevention of infectious diseases such as measles, mumps, rubella, hepatitis B, influenza, and human papillomavirus (HPV)
• Travel vaccinations for diseases endemic to certain regions
• Vaccination for at-risk populations, such as those with compromised immune systems or specific occupational exposures

Dosage

Children: Dosage varies by vaccine type and age; refer to the BNF for Children for specific dosing information.

Adults: Dosage varies by vaccine type and indication; refer to specific guidelines for each vaccine.

Mechanism of action

Vaccines work by mimicking an infection. They introduce a harmless component of a pathogen (antigen) to the immune system, prompting the body to produce an immune response. This includes the generation of antibodies and memory cells that provide long-term immunity. Upon subsequent exposure to the actual pathogen, the immune system is primed to respond more rapidly and effectively.

Pharmacodynamics

The pharmacodynamics of vaccines involves the activation of both humoral and cellular immunity. Vaccines stimulate B cells to produce antibodies against the pathogen, while T cells are activated to destroy infected cells. This dual response helps to establish immunological memory, which enables a faster and more robust response upon re-exposure to the pathogen.

Pharmacokinetics

Vaccines are administered via various routes, including intramuscular, subcutaneous, and oral. After administration, the antigens are presented to antigen-presenting cells, which activate T cells and stimulate B cell proliferation and differentiation. The half-life of vaccine-induced immunity varies depending on the type of vaccine, with some providing lifelong immunity and others requiring booster doses to maintain protection.

Contra-indications

• Severe allergic reaction (anaphylaxis) to a component of the vaccine
• Severe immunocompromised state for live attenuated vaccines

Adverse effects

• Local reactions at the injection site (pain, redness, swelling)
• Fever
• Fatigue
• Headache
• Muscle pain
• Joint pain
• Nausea

Interactions

• Immunosuppressive medications may reduce vaccine efficacy
• Concurrent administration of some vaccines may require spacing to optimize immune response

Precautions

• History of allergic reactions to vaccines or vaccine components
• Pregnancy (specific vaccines may be contraindicated)
• Moderate to severe acute illness with or without fever

Pregnancy

Consult healthcare provider. Some vaccines are contraindicated during pregnancy, while others are recommended.

Breast-feeding

Generally considered safe, but consult healthcare provider regarding specific vaccines.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Liquid suspension for injection
• Lyophilized powder for reconstitution